Anavex Life Sciences Corp (AVXL)

[JWC3]

Suppose that half of the 400,000 Alzheimer Disease AD afflicted can afford to pay the $3000 per year that ANAVEX might charge for the SAS prescription cost of A 2-73. Also assume that half of those act quickly enough to get their doctor to apply for it and receive authorization within the next 3 months. So 100,000 AD PATIENTS will be taking A 2-73 by December 1, 2020. So each month after that ANAVEX will receive (3000)x 100000/12 = $25M/month = $300M/year! ANAVEX will have a market cap of $1.5B, and a stock price of $30!